Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: Phase III (AXIS) trial

55Citations
Citations of this article
91Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Axitinib demonstrated greater progression-free survival vs sorafenib in a phase III study of previously treated patients with metastatic renal cell carcinoma. Here, we report patient-reported kidney-specific symptoms and health status, measured by the Functional Assessment of Cancer Therapy (FACT) Kidney Cancer Symptom Index (FKSI) and the European Quality of Life self-report questionnaire (EQ-5D).Methods:In all, 723 patients received axitinib (starting dose 5 mg twice daily (b.i.d.)) or sorafenib (400 mg b.i.d.). The FKSI-15, including the disease-related symptoms (FKSI-DRS) subscale, was administered on day 1 before dosing, every 4 weeks and at end of treatment (EOT)/withdrawal. Statistical methods included a mixed-effects repeated-measures model.Results:At baseline, patients in both arms had relatively high mean FSKI-15 and FKSI-DRS scores, comparable to the general US population. Subsequent on-treatment overall mean scores were similar between axitinib and sorafenib, and there was no substantial decline during treatment. Scores substantially worsened at EOT, mainly due to disease progression.Conclusion:Patient-reported outcomes were comparable for second-line axitinib and sorafenib and were maintained at relatively high levels while on treatment, but worsened at EOT. As duration of treatment was longer with axitinib than sorafenib, time to worsening of symptoms can be delayed longer with axitinib. © 2013 Cancer Research UK. All rights reserved.

Cite

CITATION STYLE

APA

Cella, D., Escudier, B., Rini, B., Chen, C., Bhattacharyya, H., Tarazi, J., … Motzer, R. (2013). Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: Phase III (AXIS) trial. British Journal of Cancer, 108(8), 1571–1578. https://doi.org/10.1038/bjc.2013.145

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free